Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Jane, Children’s Hospital: cultural challenge Scientists  to Scientists Hospital and University – no challenge, CONSTRAINTS in Academic scientist vs Research in Industry, NIH funded , gov’t keep license, Hugh Institute their Legal, right to Publish, commercial company requested to sponsor research with given scientists asked to hold publication work done at Children’s, transaction fell through.Protecting IP strong at Academic Institution, matching license, spin off, potential partners need to know the assets, rare disease in many departments, clinical trials, Genomics, choice between license, vs. spin off, license is easier, if PI wants start up the support will be given, inventions needs outside help, clinical trials very sophisticated.

Kathy Bowdish, Sanofi, Sun Rise, Scientific Collaboration at level of PI, culture difference, NEW company creation, work with Academia, on sponsored Research, Investigator wished to form a company, Sanofi sponsored, Strategic rights, will allow research to stay nimble, connection scientist at Sanofi and the outsiders, stay outside has benefits, Sponsor Research around the World vs. collaboration around clinical assets, Sunrise, co-creation in early stage, bioventure models, 3-5 years plan, agreement set upfront, and funds go in, IP protection: is IP  too fragmented? Is it registrable?? Back door for IP

James Tobin – Regional approach, Boston, Shanghai, syndicate, J&J devices, therapeutics, consumer products, Bariatrics, Broad Institute is an example of HYBRID model, Academic looks like BIOTECH, Academia now transforms to look like Biotech, at J&J, sharing alignment, bring assests from outside to inside, intangibles, Innovation Center had an Equity investment arm inside, getting value for the investment, Outside – late stage acquisition, proof of concept. Creation approach, early investors, create by syndication with outsider so we led as Partner of choice. Get part of the IP.

Judith Dunn, Translational Research Center in NY, Collaboration Disease Foundations, share talent across organizations: Academic collaborations, shared risk in discovery, Scientist easy to get together, collaborate with Academia, early before a great prior art was created, stay outside as long as possible. Several possibilities, each large Pharma used several approaches, strength to be put together. Being Partner of Choice,

Ben Thorner, Boston, Innovation Lab Merck, ex- Amgen, Novartis. Tracks themes: Collaboration with Academic centers, Resources put together, complimentary resources, scientific and infrastructure, Program and Molecules Not invented here bring them inside for clinical piece,  external , lastly, Venture Fund, Lynn Lerner, Strategic Investments opportunities explored, Merck Research Labs in Boston, collaborate with this part of Merck with the Innovation Hub. Publication issue can be solved, get a patent filings before publication on a molecule that both sides wish to develop with undue delay. Unlike other corporate Ventures, Merck, is identifying opportunities without preconceived notions – WHAT WILL LEAD TO EXTRAORDINARY BREAKTHROUGH, be flexible in making investment, research collaboration – shopping approach, built in network across labs all have relations from the past, where are opportunities in neighbor institution, Transactional relations, Check goes to University. What both organization bring to the table, molecular compound for specific pathways. Fracture IP landscape from many Labs, same flavor of inventions, bring together scientific teams.